Literature DB >> 29027243

Phenytoin: its potential as neuroprotective and retinoprotective drug.

Flavia Chiosi1, Jan Keppel Hesselink2, Michele Rinaldi3, Silvio Di Staso4, Silvia Bartollino1, Ciro Costagliola1.   

Abstract

Keywords:  neuroprotection; optic neuritis; phenytoin; retinoprotection

Mesh：

Substances：

Year:  2017        PMID： 29027243      PMCID： PMC5736838          DOI： 10.1111/bcp.13435

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

Review 1.  Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis.

Authors:  Axel Petzold; Johannes F de Boer; Sven Schippling; Patrik Vermersch; Randy Kardon; Ari Green; Peter A Calabresi; Chris Polman
Journal:  Lancet Neurol       Date:  2010-09       Impact factor: 44.182

2.  Phenytoin: its potential as neuroprotective and retinoprotective drug.

Authors:  Flavia Chiosi; Jan Keppel Hesselink; Michele Rinaldi; Silvio Di Staso; Silvia Bartollino; Ciro Costagliola
Journal:  Br J Clin Pharmacol       Date:  2017-10-12       Impact factor: 4.335

3.  Multiple actions of phenytoin on mouse spinal cord neurons in cell culture.

Authors:  M J McLean; R L Macdonald
Journal:  J Pharmacol Exp Ther       Date:  1983-12       Impact factor: 4.030

4.  Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo.

Authors:  Albert C Lo; Carl Y Saab; Joel A Black; Stephen G Waxman
Journal:  J Neurophysiol       Date:  2003-08-06       Impact factor: 2.714

Review 5.  Vision and vision-related outcome measures in multiple sclerosis.

Authors:  Laura J Balcer; David H Miller; Stephen C Reingold; Jeffrey A Cohen
Journal:  Brain       Date:  2014-11-28       Impact factor: 13.501

6.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.

Authors:  Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2015-10-12       Impact factor: 16.971

7.  Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.

Authors:  Rhian Raftopoulos; Simon J Hickman; Ahmed Toosy; Basil Sharrack; Shahrukh Mallik; David Paling; Daniel R Altmann; Marios C Yiannakas; Prasad Malladi; Rose Sheridan; Ptolemaios G Sarrigiannis; Nigel Hoggard; Martin Koltzenburg; Claudia A M Gandini Wheeler-Kingshott; Klaus Schmierer; Gavin Giovannoni; David H Miller; Raju Kapoor
Journal:  Lancet Neurol       Date:  2016-01-26       Impact factor: 44.182

8.  Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.

Authors:  Sarah Al-Izki; Gareth Pryce; Deborah J R Hankey; Katie Lidster; Stephanie M von Kutzleben; Lorcan Browne; Lisa Clutterbuck; Cristina Posada; A W Edith Chan; Sandra Amor; Victoria Perkins; Wouter H Gerritsen; Kim Ummenthum; Regina Peferoen-Baert; Paul van der Valk; Alexander Montoya; Simon P Joel; John Garthwaite; Gavin Giovannoni; David L Selwood; David Baker
Journal:  Brain       Date:  2013-11-27       Impact factor: 13.501
  8 in total
  3 in total

1.  Phenytoin: its potential as neuroprotective and retinoprotective drug.

Authors:  Flavia Chiosi; Jan Keppel Hesselink; Michele Rinaldi; Silvio Di Staso; Silvia Bartollino; Ciro Costagliola
Journal:  Br J Clin Pharmacol       Date:  2017-10-12       Impact factor: 4.335

2.  In Vivo Scanning Laser Confocal Microscopy of Conjunctival Goblet Cells in Medically-controlled Glaucoma.

Authors:  Silvio DI Staso; Luca Agnifili; Marco Ciancaglini; Gianluca Murano; Enrico Borrelli; Leonardo Mastropasqua
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

Review 3.  In Vivo Analysis of Prostaglandins-induced Ocular Surface and Periocular Adnexa Modifications in Patients with Glaucoma.

Authors:  Silvio DI Staso; Luca Agnifili; Sara Cecannecchia; Angela DI Gregorio; Marco Ciancaglini
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.